121 related articles for article (PubMed ID: 6892197)
21. Platinum in blood mononuclear cells from patients after cisplatin therapy.
Sunderman FW; Sporn J; Hopfer SM; Sweeney KR; Chakraborty NG; Greenberg B
Ann Clin Lab Sci; 1990; 20(6):379-84. PubMed ID: 2073087
[TBL] [Abstract][Full Text] [Related]
22. Disposition and distribution of platinum following parenteral administration of cis-dichlorodiammineplatinum(II) to animals.
Litterst CL; LeRoy AF; Guarino AM
Cancer Treat Rep; 1979; 63(9-10):1485-92. PubMed ID: 498147
[TBL] [Abstract][Full Text] [Related]
23. [Pharmacokinetics of high-dose cisplatin administration (relationship between pharmacokinetics and administration schedule)].
Yamamoto N; Yanagi K; Matuyama H; Shimizu K; Mitsui H; Shimabukuro T; Yamamoto M; Sakatoku J; Fujita T; Matsuoka K
Hinyokika Kiyo; 1987 Nov; 33(11):1760-5. PubMed ID: 3445857
[TBL] [Abstract][Full Text] [Related]
24. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin.
Meerum Terwogt JM; Groenewegen G; Pluim D; Maliepaard M; Tibben MM; Huisman A; ten Bokkel Huinink WW; Schot M; Welbank H; Voest EE; Beijnen JH; Schellens JM
Cancer Chemother Pharmacol; 2002 Mar; 49(3):201-10. PubMed ID: 11935212
[TBL] [Abstract][Full Text] [Related]
25. [The pharmacokinetics of cisplatin and its influence on renal functions based on different infusion methods].
Takahashi A; Takagi M; Hishida H; Saji E; Takagi N; Amano H; Ogura Y
Gan To Kagaku Ryoho; 1987 Oct; 14(10):2944-50. PubMed ID: 3116947
[TBL] [Abstract][Full Text] [Related]
26. Kinetics of cis-dichlorodiammineplatinum.
Gormley PE; Bull JM; LeRoy AF; Cysyk R
Clin Pharmacol Ther; 1979 Mar; 25(3):351-7. PubMed ID: 761445
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function.
Harland SJ; Newell DR; Siddik ZH; Chadwick R; Calvert AH; Harrap KR
Cancer Res; 1984 Apr; 44(4):1693-7. PubMed ID: 6367971
[TBL] [Abstract][Full Text] [Related]
28. [Pharmacokinetic study of cisplatin and sodium thiosulfate in two-route-infusion chemotherapy].
Ikeda K
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):1026-31. PubMed ID: 3963847
[TBL] [Abstract][Full Text] [Related]
29. Pharmacodynamics of cisplatin in human head and neck cancer: correlation between platinum content, DNA adduct levels and drug sensitivity in vitro and in vivo.
Welters MJ; Fichtinger-Schepman AM; Baan RA; Jacobs-Bergmans AJ; Kegel A; van der Vijgh WJ; Braakhuis BJ
Br J Cancer; 1999 Jan; 79(1):82-8. PubMed ID: 10408697
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of liposomal cisplatin (lipoplatin) in combination with 5-FU in patients with advanced head and neck cancer: first results of a phase III study.
Jehn CF; Boulikas T; Kourvetaris A; Possinger K; Lüftner D
Anticancer Res; 2007; 27(1A):471-5. PubMed ID: 17352269
[TBL] [Abstract][Full Text] [Related]
31. [Pharmacokinetics of plasma and cerebrospinal fluid cisplatin in patients with malignant glioma and metastatic brain tumor after selective intraarterial or intravenous and intracarotid administration of etoposide and cisplatin].
Nakagawa H; Miyawaki Y; Tokiyoshi K; Tsuruzono K; Yamada M; Kanayama T; Hayakawa T
No Shinkei Geka; 1994 Jan; 22(1):35-42. PubMed ID: 8295700
[TBL] [Abstract][Full Text] [Related]
32. Platinum concentrations in bile and plasma following rapid and 6-hour infusions of cis-dichlorodiammineplatinum(II).
Casper ES; Kelsen DP; Alcock NW; Young CW
Cancer Treat Rep; 1979; 63(11-12):2023-5. PubMed ID: 575066
[No Abstract] [Full Text] [Related]
33. Comparative pharmacokinetics of four platinum cytostatics in rats.
Láznícková A; Filipová M; Láznícek M; Drobník J; Svoboda D; Kvĕtina J
Neoplasma; 1987; 34(2):173-81. PubMed ID: 3600883
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics and protein binding of cis-dichlorodiammine platinum (II) administered as a one hour or as a twenty hour infusion.
Gullo JJ; Litterst CL; Maguire PJ; Sikic BI; Hoth DF; Woolley PV
Cancer Chemother Pharmacol; 1980; 5(1):21-6. PubMed ID: 6161715
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days.
Vouillamoz-Lorenz S; Buclin T; Lejeune F; Bauer J; Leyvraz S; Decosterd LA
Anticancer Res; 2003; 23(3C):2757-65. PubMed ID: 12926110
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetic study in carboplatin, cisplatin and 5-fluorouracil regimen for advanced oesophageal cancer.
Leger-Enreille A; Cure H; Pezet D; Bargnoux PJ
Anticancer Res; 1994; 14(6A):2327-9. PubMed ID: 7825967
[TBL] [Abstract][Full Text] [Related]
37. Clinical phase I study of paclitaxel followed by cisplatin in advanced head and neck squamous cell carcinoma.
Hanauske AR; Schilling T; Heinrich B; Kau R; Herzog M; Quasthoff S; Bochtler H; Diergarten K; Rastetter J
Semin Oncol; 1995 Dec; 22(6 Suppl 14):35-9. PubMed ID: 8553082
[TBL] [Abstract][Full Text] [Related]
38. Plasma and tumor concentrations of cisplatin following intraperitoneal infusion or bolus injection with or without continuous low-dose-rate irradiation.
Fu KK; DeGregorio MW; Phillips JW
NCI Monogr; 1988; (6):123-7. PubMed ID: 3281027
[TBL] [Abstract][Full Text] [Related]
39. In vitro cytotoxicity, pharmacokinetics and ex vivo pharmacodynamics of a new platinum compound, cis-malonato [(4R,5R-4,5-bis(aminomethyl)-1,3-dioxolane-2-spiro-1'-cyclopentane] platinum (II).
Kim DK; Kim HT; Cho YB; Kim TS; Kim KH; Hong WS
Anticancer Res; 1996; 16(1):251-6. PubMed ID: 8615617
[TBL] [Abstract][Full Text] [Related]
40. Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule.
Schilder RJ; LaCreta FP; Perez RP; Johnson SW; Brennan JM; Rogatko A; Nash S; McAleer C; Hamilton TC; Roby D
Cancer Res; 1994 Feb; 54(3):709-17. PubMed ID: 8306332
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
